文献速递头颈外科

免疫检查点抑制剂后挽救化疗对复发或转移性头颈癌的影响

Impact of salvage chemotherapy after immune checkpoint inhibitor for recurrent or metastatic head and neck cancer.
PubMed 文献 · Head Neck · 2024-01-16

本研究纳入109例复发或转移性头颈癌患者,比较免疫检查点抑制剂单药治疗失败后接受挽救化疗与否及不同方案的生存差异。55例接受挽救化疗者的总生存期长于未接受者;紫杉醇联合西妥昔单抗与紫杉醇单药的总生存期和无进展生存期2相似;免疫相关不良事件的发生不影响无进展生存期2和总生存期。

要点

  • 免疫检查点抑制剂单药治疗失败后接受挽救化疗的55例患者总生存期长于未接受挽救化疗者。
  • 紫杉醇联合西妥昔单抗与紫杉醇单药的总生存期和无进展生存期2相似。
  • 免疫相关不良事件的发生不影响无进展生存期2和总生存期。

核心结论

  • 挽救化疗可改善复发或转移性头颈癌患者的生存结局。
  • 除紫杉醇联合西妥昔单抗外,紫杉醇单药也被认为是有效的挽救化疗方案。
  • 无论是否出现免疫相关不良事件,挽救化疗均有效。

研究设计与样本

  • 本研究纳入109例患者,按挽救化疗方案分层比较总生存期和无进展生存期2。

主要发现

  • 109例患者中55例在免疫检查点抑制剂单药治疗失败后接受挽救化疗。
  • 这55例接受挽救化疗患者的总生存期长于未接受挽救化疗的患者。
  • 紫杉醇联合西妥昔单抗治疗者与紫杉醇单药治疗者的总生存期和无进展生存期2相似。
  • 免疫相关不良事件的发生不影响无进展生存期2和总生存期。

临床怎么用

  • 作者认为,除紫杉醇联合西妥昔单抗外,紫杉醇单药也可考虑作为有效的挽救化疗方案。
  • 作者认为,挽救化疗可改善复发或转移性头颈癌患者的生存结局,且无论是否出现免疫相关不良事件均有效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is unclear witch regimen is optimal as salvage chemotherapy (SCT) after immune checkpoint inhibitor (ICI) monotherapy for recurrent or metastatic head and neck cancer (RM-HNC). METHODS: This study enrolled 109 patients. Overall survival (OS) and progression-free survival 2 (PFS2) were compared between patients stratified by SCT regimen. RESULTS: Of the 109 patients, 55 underwent SCT after the failure of ICI monotherapy. The OS of these 55 patients was longer than that of patients who did not undergo SCT. The OS and PFS2 were similar between patients treated with paclitaxel (PTX) and cetuximab (Cmab) combination and those treated with PTX monotherapy. The occurrence of irAEs did not impact PFS2 nor OS. CONCLUSIONS: SCT can improve the survival outcomes of patients with RM-HNC. In addition to PTX and Cmab, PTX monotherapy is also considered an effective SCT regimen. SCT is effective regardless of the presence or absence of irAEs.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Matoba T, Minohara K, Kawakita D, et al. Impact of salvage chemotherapy after immune checkpoint inhibitor for recurrent or metastatic head and neck cancer. Head Neck. 2024. PMID: 38229255. doi:10.1002/hed.27643

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。